Ryan Livingston

The updated guideline offers recommendations for RBC transfusions and iron management, while continuing to prioritize patient-centered care.

The NDA is based on positive 52-week data from the phase 3 VERIFY clinical trial, which demonstrated rusfertide’s capacity to reduce phlebotomy dependency.

Catch up with major FDA decisions, critical conference news, and more.

A recent retrospective cohort analysis of the ACCORD phase 3 study has revealed a correlation between higher index values and increased mortality risk.

Catch up on the most impactful headlines in dyslipidemia from all of 2025 with our Year in Review.

The CRL notes that additional mechanistic and natural history data have not altered the previous review conclusions.

The novel oral NMDA receptor antagonist, sigma-1 agonist, and aminoketone CYP2D6 inhibitor has indicated its efficacy and safety across 3 clinical trials.

The FDA has issued a CRL for selective cortisol modulator relacorilant, citing a need for more evidence of effectiveness.

The FDA has approved oral neurokinin-1 receptor antagonist tradipitant for the prevention of motion sickness, marking the first approval in decades.

Catch up on the most impactful headlines in hormonal disorders from all of 2025 with our Year in Review.

Catch up on the most impactful headlines in HF from all of 2025 with our Year in Review.

Catch up on the most impactful headlines in cardiology from all of 2025 with our Year in Review.

The FDA has approved small-molecule pyruvate kinase R activator mitapivat for the treatment of anemia in adults with alpha- or beta-thalassemia.

Catch up on the most impactful headlines in dyslipidemia from all of 2025 with our Year in Review.

The FDA has approved an sNDA for the FUROSCIX On-body Infusor in pediatric patients and accepted another for the FUROSCIX ReadyFlow Autoinjector.

Catch up on the most impactful headlines in ophthalmology from all of 2025 with our Year in Review.

The FDA’s decision is based on positive results from the phase 3 THRIVE and THRIVE-2 clinical trials, which showed veligrotug’s efficacy and rapid onset of benefits.

Catch up on the most impactful headlines in T2D from all of 2025 with our Year in Review.

Results from the ATTAIN-MAINTAIN phase 3 study have displayed orforglipron’s efficacy in maintaining weight loss without major safety concerns.

Experts redefine obesity, distinguishing between preclinical and clinical forms, aiming to improve diagnosis and treatment strategies for better health outcomes.

Following the addition of a clinical study report to the NDA on December 12, the regulatory agency has extended the review period for the RASP inhibitor.

FDA approves lerodalcibep, a groundbreaking PCSK9 inhibitor, offering a monthly injection for LDL cholesterol reduction in patients with HoFH.

The FDA has approved etripamil nasal spray for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm.

Announced by Cogent Biosciences, these data indicate bezuclastinib’s capacity for improving patient-reported symptoms of mast cell burden.

Catch up with major trial results, key clinician insights, and more.

Catch up with major FDA decisions, critical conference news, and more.

Results from the INTIMET study have shown no significant differences between metformin and placebo in liver, muscle, or adipose tissue insulin resistance.

The submission follows positive results from the BaxHTN trial, which saw the investigational aldosterone synthase inhibitor improve systolic BP versus placebo.

The acceptance comes on the heels of positive topline results comparing the new device to the current on-body infusor.

The investigational unimolecular GLP-1 and amylin receptor agonist substantially improved weight loss in a phase 2 trial.